東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Resistance of targeted therapies exc...

Ferreri, Andres J. M.

FindBook

Google Book

Amazon

博客來

Resistance of targeted therapies excluding antibodies for lymphomas

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Resistance of targeted therapies excluding antibodies for lymphomas/ edited by Andres J. M. Ferreri.
其他作者:	Ferreri, Andres J. M.
出版者:	Cham :Springer International Publishing : : 2018.,
面頁冊數:	xiii, 138 p. :ill. (some col.), digital ;24 cm.
內容註:	Chapter 1 BTK inhibitors: focus on ibrutinib and similar agents -- Chapter 2 BCL2 Inhibitors: insights into resistance -- Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib -- Chapter 4 IMiD - immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms -- Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents -- Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents.
Contained By:	Springer eBooks
標題:	Lymphomas - Chemotherapy. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-75184-9
ISBN:	9783319751849

Resistance of targeted therapies excluding antibodies for lymphomas
Resistance of targeted therapies excluding antibodies for lymphomas[electronic resource] /edited by Andres J. M. Ferreri. - Cham :Springer International Publishing :2018. - xiii, 138 p. :ill. (some col.), digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.172196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.17..

Chapter 1 BTK inhibitors: focus on ibrutinib and similar agents -- Chapter 2 BCL2 Inhibitors: insights into resistance -- Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib -- Chapter 4 IMiD - immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms -- Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents -- Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents.

In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance.

ISBN: 9783319751849

Standard No.: 10.1007/978-3-319-75184-9doiSubjects--Topical Terms:

3307755
Lymphomas
--Chemotherapy.

LC Class. No.: RC280.L9 / R475 2018

Dewey Class. No.: 616.99446061

Resistance of targeted therapies excluding antibodies for lymphomas
LDR:02320nmm a2200325 a 4500 001 2136402
003 DE-He213
005 20180830165534.0
006 m d
007 cr nn 008maaau
008 181117s2018 gw s 0 eng d
020 $a 9783319751849 $q (electronic bk.)
020 $a 9783319751832 $q (paper)
024 7 $a 10.1007/978-3-319-75184-9 $2 doi
035 $a 978-3-319-75184-9
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.L9 $b R475 2018
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99446061 $2 23
090 $a RC280.L9 $b R433 2018
245 0 0 $a Resistance of targeted therapies excluding antibodies for lymphomas $h [electronic resource] / $c edited by Andres J. M. Ferreri.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a xiii, 138 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Resistance to targeted anti-cancer therapeutics, $x 2196-5501 ; $v v.17
505 0 $a Chapter 1 BTK inhibitors: focus on ibrutinib and similar agents -- Chapter 2 BCL2 Inhibitors: insights into resistance -- Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib -- Chapter 4 IMiD - immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms -- Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents -- Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents.
520 $a In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance.
650 0 $a Lymphomas $x Chemotherapy. $3 3307755
650 0 $a Drug targeting. $3 768297
650 1 4 $a Biomedicine. $3 890831
650 2 4 $a Cancer Research. $3 891172
650 2 4 $a Molecular Medicine. $3 890952
700 1 $a Ferreri, Andres J. M. $3 3307753
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Resistance to targeted anti-cancer therapeutics ; $v v.17. $3 3307754
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-75184-9
950 $a Biomedical and Life Sciences (Springer-11642)